A high molar activity 18F-labeled TAK-875 derivative for PET imaging of pancreatic β-cells

Mark H. Dornan(Centre Hospitalier de l’Université de Montréal), Jean N. DaSilva(Centre Hospitalier de l’Université de Montréal), Barry J. Bedell(McGill University), Julien Ghislain(Centre Hospitalier de l’Université de Montréal), Vincent Poitout(Montreal General Hospital), Antonio Aliaga(Montreal Neurological Institute and Hospital), José‐Mathieu Simard(Centre Hospitalier de l’Université de Montréal), Guoming Xiong(McGill University Health Centre), D. R. Petrenyov(Centre Hospitalier de l’Université de Montréal)
EJNMMI Radiopharmacy and Chemistry
December 1, 2018
10.1186/s41181-018-0051-2
Cited by 2

Related Papers

β-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes
|Diabetes|2004|914
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
|The Lancet Neurology|2012|846
The Use of <sup>18</sup>F-FDG PET in the Diagnosis of Cardiac Sarcoidosis: A Systematic Review and Metaanalysis Including the Ontario Experience
|Journal of Nuclear Medicine|2012|512
Elimination of the Acetaminophen Interference in an Implantable Glucose Sensor
|Analytical Chemistry|1994|183
<sup>18</sup>F-FDG PET Imaging of Myocardial Viability in an Experienced Center with Access to <sup>18</sup>F-FDG and Integration with Clinical Management Teams: The Ottawa-FIVE Substudy of the PARR 2 Trial
|Journal of Nuclear Medicine|2010|154